TrialBritish journal of clinical pharmacology2022

A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.

Angela Sinn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.